Ceftazidime-avibactam
Ceftazidime-avibactam is a combination antibacterial Therapy consisting of the third-generation cephalosporin ceftazidime and the non-β-lactam β-lactamase inhibitor avibactam.
Ceftazidime-avibactam is a combination antibacterial Therapy consisting of the third-generation cephalosporin ceftazidime and the non-β-lactam β-lactamase inhibitor avibactam. It is designed to restore or enhance ceftazidime activity against many Gram-negative bacteria that produce β-lactamases, including some carbapenemase-producing Enterobacterales. Clinically, it is used for serious multidrug-resistant infections in settings where standard β-lactam Therapy may be ineffective.
Its medical significance lies in its role as a targeted option for difficult-to-treat Gram-negative infections, particularly those caused by organisms such as Klebsiella pneumoniae, Enterobacter cloacae complex, and Pseudomonas aeruginosa. Because resistance can emerge through β-lactamase evolution, porin changes, efflux upregulation, or acquisition of metallo-β-lactamases such as NDM, ceftazidime-avibactam is often discussed alongside aztreonam, aztreonam-avibactam, cefiderocol, meropenem-vaborbactam, and imipenem/relebactam in the context of contemporary antimicrobial stewardship and resistance management.
Where the papers sit
10 papers from the last 6 months study ceftazidime-avibactam directly · updated from PubMed 12 Nov 2026
Study type 0 clinical trials · 3 observational · 5 human data · 1 preclinical · 1 unclassified
Themes 3 themes · 1 paradigm shift
-
KPC Klebsiella Resistance
KPC-producing Klebsiella pneumoniae is developing ceftazidime-avibactam resistance during treatment and transmission. Recurrent KPC-2, KPC-3, KPC-25, KPC-33 and KPC-127 variants point to evolving carbapenemase escape, sometimes with hypermutator phenotypes. Whole genome sequencing and in vitro evolution link resistance to outbreaks, fitness differences and intracranial infection. Cefiderocol and mutant-prevention strategies are being assessed as alternatives or complements, but clinical management remains unresolved.
5 papers · 50%
-
Resistant Gram-Negative Management
Clinical use of ceftazidime-avibactam is being paired with resistance surveillance and susceptibility testing in difficult Gram-negative infections. Pseudomonas aeruginosa resistance is linked to the OXA-1381 W157L Ω-loop variant, highlighting a specific route to treatment failure. Hospital experience and phenotypic screening for metallo-β-lactamases and extended-spectrum β-lactamases address how reliably therapy can be deployed. The work supports local testing and stewardship, but does not establish one preferred management strategy.
3 papers · 30%
-
Real-World Treatment Outcomes
Ceftazidime-avibactam is being evaluated as rescue therapy for carbapenem-resistant Enterobacterales pneumonia and bacteremia. The recurring endpoints are effectiveness, mortality and risk factors for treatment failure in severely ill patients. Septic shock, acute kidney injury, chronic illness and low serum albumin emerge as clinically important prognostic features. Retrospective data support use in multidrug-resistant infections, while the optimal selection and timing of therapy remain open.
2 papers · 20%
Ceftazidime-avibactam therapy can actively drive diverse within-host resistance evolution rather than simply fail against pre-existing resistance
The study of an ESBL-producing Pseudomonas aeruginosa isolate found that treatment selected the novel OXA-1381 variant and increased ceftazidime-avibactam resistance while restoring carbapenem susceptibility 42615933Aug. The study of an ICU outbreak caused by ST512 KPC-producing Klebsiella pneumoniae likewise found that a susceptible index isolate acquired KPC-270 during therapy, with resistance emerging to both ceftazidime-avibactam and cefiderocol 42604655Aug. The study of KPC-producing K. pneumoniae in intracranial infection independently documented sequential KPC-25 and KPC-127 variants during treatment, with later resistance extending to both ceftazidime-avibactam and carbapenems 42385193Jul. Together, these findings replace the assumption that ceftazidime-avibactam is a stable endpoint once the infecting isolate is initially susceptible: exposure can become the selective force generating new resistance mechanisms, including collateral or expanded resistance, so treatment requires attention to evolutionary change and not only baseline susceptibility.
Papers
The 10 papers from the last 6 months that study ceftazidime-avibactam directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
KPC Klebsiella Resistance (5)
- Repeated emergence and fitness heterogeneity of KPC-33 in ST11 Klebsiella pneumoniae under ceftazidime-avibactam pressure. Antimicrobial agents and chemotherapy · 10 Sept 2026 PMID 42720552
- Single unscreened carrier triggered ICU outbreak of a KPC-producing Klebsiella pneumoniae which acquired in vivo resistance to ceftazidime-avibactam, and cefiderocol. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 16 Aug 2026 PMID 42604655
- Emergence of mutHV76G in carbapenem-resistant Klebsiella pneumoniae disrupts DNA mismatch repair and results in a hypermutator phenotype. Antimicrobial agents and chemotherapy · 5 Aug 2026 PMID 42554629
- Emergence of Ceftazidime-Avibactam-Induced KPC Variants (KPC-25/127) in Intracranial Infection and Implications for Clinical Management. MicrobiologyOpen · 1 Jul 2026 PMID 42385193
- Addressing therapeutic options for KPC-3-producing ST307-Klebsiella pneumoniae: insights from in vitro evolution and mutant prevention strategies. Antimicrobial agents and chemotherapy · 1 Jul 2026 PMID 42383991
Resistant Gram-Negative Management (3)
- Investigation on the use of ceftazidime-avibactam at a national hospital in Vietnam. PloS one · 13 Oct 2026 PMID 42868159
- Phenotypic screening for metallo-β-lactamases and extended-spectrum β-lactamases in Pseudomonas aeruginosa using the VITEK-2 AST-N443 and Phoenix NMIC-486 cards. Microbiology spectrum · 23 Sept 2026 PMID 42775889
- In vivo emergence of ceftazidime/avibactam resistance in Pseudomonas aeruginosa driven by OXA-1381, a novel W157L Ω-loop variant of OXA-2. Antimicrobial agents and chemotherapy · 19 Aug 2026 PMID 42615933
Real-World Treatment Outcomes (2)
- Real-World Effectiveness of Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Pneumonia, Time-Stratified Risk Factors for Short- and Long-Term Mortality, and Inpatient Costs: A Multicenter Retrospective Cohort Study. Infectious diseases and therapy · 28 Jul 2026 PMID 42521922
- Ceftazidime-Avibactam Effectiveness in Carbapenem-Resistant Enterobacterales Bacteremia: A Retrospective Cohort Study in Korea. Journal of Korean medical science · 7 Jul 2026 PMID 42411238
By study type
Observational studies and case reports (3)
- Investigation on the use of ceftazidime-avibactam at a national hospital in Vietnam. PloS one · 13 Oct 2026 PMID 42868159
- Ceftazidime-Avibactam Effectiveness in Carbapenem-Resistant Enterobacterales Bacteremia: A Retrospective Cohort Study in Korea. Journal of Korean medical science · 7 Jul 2026 PMID 42411238
- Emergence of Ceftazidime-Avibactam-Induced KPC Variants (KPC-25/127) in Intracranial Infection and Implications for Clinical Management. MicrobiologyOpen · 1 Jul 2026 PMID 42385193
Human data, design not indexed (5)
- Phenotypic screening for metallo-β-lactamases and extended-spectrum β-lactamases in Pseudomonas aeruginosa using the VITEK-2 AST-N443 and Phoenix NMIC-486 cards. Microbiology spectrum · 23 Sept 2026 PMID 42775889
- Repeated emergence and fitness heterogeneity of KPC-33 in ST11 Klebsiella pneumoniae under ceftazidime-avibactam pressure. Antimicrobial agents and chemotherapy · 10 Sept 2026 PMID 42720552
- In vivo emergence of ceftazidime/avibactam resistance in Pseudomonas aeruginosa driven by OXA-1381, a novel W157L Ω-loop variant of OXA-2. Antimicrobial agents and chemotherapy · 19 Aug 2026 PMID 42615933
- Single unscreened carrier triggered ICU outbreak of a KPC-producing Klebsiella pneumoniae which acquired in vivo resistance to ceftazidime-avibactam, and cefiderocol. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 16 Aug 2026 PMID 42604655
- Addressing therapeutic options for KPC-3-producing ST307-Klebsiella pneumoniae: insights from in vitro evolution and mutant prevention strategies. Antimicrobial agents and chemotherapy · 1 Jul 2026 PMID 42383991
Preclinical: animal, cell and lab studies (1)
- Emergence of mutHV76G in carbapenem-resistant Klebsiella pneumoniae disrupts DNA mismatch repair and results in a hypermutator phenotype. Antimicrobial agents and chemotherapy · 5 Aug 2026 PMID 42554629
Unclassified: not yet indexed with MeSH (1)
- Real-World Effectiveness of Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Pneumonia, Time-Stratified Risk Factors for Short- and Long-Term Mortality, and Inpatient Costs: A Multicenter Retrospective Cohort Study. Infectious diseases and therapy · 28 Jul 2026 PMID 42521922
Written from 10 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-08-27 by GPT. Drafted by language models from published abstracts; not medical advice.